ArticleERJ open research2025
Chronic noninvasive ventilation in COPD: towards the identification of a responder phenotype.
Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Chronic noninvasive ventilation (NIV) is an effective treatment for patients with chronic hypercapnia due to COPD, but the improvement in health-related quality of life (HRQoL) varies significantly among individuals. We conducted a cluster analysis to identify clusters of patients based on their HRQoL response to chronic NIV. Patients and methods: Patients with COPD and an indication for chronic NIV were prospectively followed. Gas exchange, lung function, exercise capacity and HRQoL were measured at baseline and at 6 months. HRQoL was measured with the Severe Respiratory Insufficiency questionnaire (SRI). The cluster analysis was performed using the self-organising map-Ward's method. In addition, we compared patient and disease characteristics, changes in outcomes and survival differences between the clusters. Results: A total of 301 participants were included in the analysis and 214 patients completed the 6-month follow-up. We identified three distinct clusters of patients with equal NIV use but different HRQoL response: a "good responder" phenotype of patients, characterised by a clinically relevant improvement on the SRI, a high number of exacerbations, poor baseline HRQoL and high rates of mood disorders; a "moderate responder" phenotype, characterised by milder gas exchange and lung function impairment, and relatively preserved baseline HRQoL; and a "poor responder" phenotype of patients in whom HRQoL worsened and survival was greatly impaired. This cluster included patients with the most severe lung function and gas exchange impairment and low rates of systemic comorbidities. Conclusion: Our cluster analysis suggests that chronic NIV is most likely beneficial in patients with frequent exacerbations, severely impaired HRQoL and a high incidence of mood disorders. Future randomised controlled trials should investigate whether the different HRQoL responses between the clusters are caused by NIV.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.